Two-level ESPB in Total Knee Arthroplasty

Last updated: March 20, 2025
Sponsor: Poznan University of Medical Sciences
Overall Status: Active - Recruiting

Phase

4

Condition

Osteoarthritis

Knee Injuries

Treatment

20 ml of Ropivacaine 0.2% Injectable Solution

2 x 20 ml of Ropivacaine 0.2% Injectable Solution

2 x 20ml of Ropivacaine 0.2% Injectable Solution

Clinical Study ID

NCT06470542
9/2024
  • Ages 65-100
  • All Genders

Study Summary

Effect of two-level ESPB in Total Knee Arthroplasty

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • patients scheduled for total hip arthroplasty

  • patients aged >65 and <100 years

  • patients able to provide informed consent

  • patients able to reliably report symptoms to the research team

Exclusion

Exclusion Criteria:

  • inability to provide first-party consent due to cognitive impairment or a languagebarrier

Study Design

Total Participants: 60
Treatment Group(s): 3
Primary Treatment: 20 ml of Ropivacaine 0.2% Injectable Solution
Phase: 4
Study Start date:
November 07, 2024
Estimated Completion Date:
October 30, 2025

Study Description

Knee arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. Patients may complain of severe pain due to surgical trauma and prostheses. Regional anaesthesia methods may be performed to reduce the inflammatory response, opioid consumption, and opioid-related side effects.

Connect with a study center

  • Poznan University of Medical Sciences

    Poznan, Poznań 61-701
    Poland

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.